NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos
2 June 2016. Related: Treatment alerts, Treatment access, HIV prevention and transmission.
Treatment access
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.
Timeline for access to generic dolutegravir: what still needs to be done
1 June 2016. Related: Treatment access.
Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART
1 June 2016. Related: Treatment access.
South Africa takes bold step to provide HIV treatment for all
1 June 2016. Related: Treatment access.
New antiretrovirals could mean savings up to US $3 billion by 2025
22 March 2016. Related: Conference reports, Treatment access.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Community oppose dolutegravir and cabotegravir patents in India
22 March 2016. Related: Treatment access.
MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years
22 March 2016. Related: Treatment access.
Global Fund provides Uganda with a year of drugs to meet shortages
22 March 2016. Related: Treatment access.
Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives
22 March 2016. Related: Treatment access.
Mbeki shows no remorse for role in AIDS deaths
22 March 2016. Related: Treatment access.
Treatment as Prevention (TasP) in the UK supports access to ART at any CD4 count
1 February 2016. Related: Treatment access.
WHO 2015 guidelines: newly recommended generic ART products on the way for adults
1 February 2016. Related: Treatment access.
Better generic ART for low and middle income countries: dolutegravir at US $44 a year
1 February 2016. Related: Treatment access.
When Global Fund support ends: Sustainability lessons from transitions in Costa Rica, Fiji, Romania, and Bulgaria
1 February 2016. Related: Treatment access.
Price of MDR TB drugs could be greatly reduced with competitive generic manufacture
1 December 2015. Related: Conference reports, Treatment access, TB coinfection.
Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23
1 December 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
CHAI’s ARV market report predicts that new drugs and formulations will drive the next major drop in treatment costs
1 December 2015. Related: Treatment access.
New trade agreements threaten treatment access in Asia
1 December 2015. Related: Treatment access.
Why the 5000% price hike for pyrimethamine in the US is relevant in the UK
1 October 2015. Related: Treatment access.
Proposed TTIP trade agreement in Europe: Report shows European Commission’s access to medicines commitments are ‘empty gestures’
1 October 2015. Related: Treatment access.
Australian doctors advice for buying generic sofosbuvir for HepC
1 October 2015. Related: Treatment access, Hepatitis coinfection.
“We will win or lose the fight against AIDS in next five years”: UNAIDS and Lancet commission report
1 August 2015. Related: Treatment access, On the web.
The option for same day antiretroviral therapy on diagnosis: the future model for HIV care
1 August 2015. Related: Conference reports, Treatment strategies, Treatment access, Treatment advocacy, Other news.
New directions in the 2015 WHO ART guidelines
1 August 2015. Related: Conference reports, Treatment access, Guidelines.
Large variation across countries in meeting UNAIDS 90-90-90 targets
1 August 2015. Related: Conference reports, Treatment access.
Generic dolutegravir submitted to FDA for tentative approval
1 June 2015. Related: Antiretrovirals, Treatment access.
Lopinavir/ritonavir pellets tentatively approved by the FDA
1 June 2015. Related: Treatment access.
Sofosbuvir access: new patent challenges to sofosbuvir
1 June 2015. Related: Treatment access, Hepatitis coinfection.
Hepatitis C drug access: Europe is the new Africa
29 January 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
Morocco’s acceptance of EU patent law threatens millions of lives
29 January 2015. Related: Treatment access.
Global Fund releases end-2104 numbers
29 January 2015. Related: Treatment access.
India rejects Gilead’s patent application for sofosbuvir
29 January 2015. Related: Treatment access, Hepatitis coinfection.
Savings to the NHS predicted from switching to generic antiretrovirals
1 December 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Pill A, Pill B: simplified second-line treatment for low-income countries
1 August 2014. Related: Conference reports, Antiretrovirals, Treatment access.
UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030
1 August 2014. Related: Conference reports, Treatment access.
No difference in overall anaemia rate with reduced dose AZT
1 August 2014. Related: Conference reports, Treatment strategies, Treatment access.
Rationalising the paediatric antiretroviral formulary in Malawi
1 August 2014. Related: Conference reports, Treatment access, Paediatric care.
New ARV prescribing guidelines for London (2014)
1 August 2014. Related: Treatment access, Guidelines.
Global update: hepatitis C treatment activism
19 July 2014. Related: Pipeline report, Treatment access, Hepatitis coinfection.
Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed
27 May 2014. Related: Conference reports, Treatment access.
FDA approvals of generic ARVS
24 March 2014. Related: Treatment access.
Dolutegravir approved in Europe
1 February 2014. Related: Antiretrovirals, Treatment access.
BMS to add atazanavir to Patent Pool
1 February 2014. Related: Treatment access.
Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal
1 February 2014. Related: Treatment access.
Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law
1 February 2014. Related: Treatment access.
Obama increases US contribution to Global Fund to $5 billion over three years
1 December 2013. Related: Treatment access.
HIV struggle in South Africa undermined by medicine stockouts and mismanagement
1 December 2013. Related: Treatment access.
Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)
1 October 2013. Related: Treatment strategies, Treatment access, Guidelines.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
From sky high to CHAI* – what needs to be done about dolutegravir pricing?
1 October 2013. Related: Antiretrovirals, Treatment access.
UK pledges £1 billion for Global Fund
1 October 2013. Related: Treatment access.
France pledges $1.4 billion for Global Fund
1 October 2013. Related: Treatment access.
UNAIDS reports new HIV infections are reduced by one-third compared to 2001
1 October 2013. Related: Treatment access.
WHO 2013 guidelines: what about the missing formulations?
25 July 2013. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
Ending global use of d4T: UNITAID to tip market to safer alternatives
25 July 2013. Related: Treatment access, Side effects.
TRIPS extension for least developed countries
25 July 2013. Related: Treatment access.
Community request Gilead to study and develop separate formulation of new tenofovir prodrug
25 July 2013. Related: Antiretrovirals, Treatment access.
Upcoming WHO ART guidelines (2013)
29 May 2013. Related: Treatment access.
Fixed dose combination efavirenz/tenofovir/FTC for South Africa
29 May 2013. Related: Treatment access.
New UNAIDS report highlights progress in the AIDS response in Africa
29 May 2013. Related: Treatment access.
Indian Supreme Court delivers verdict in Novartis case: decision safeguards access to affordable medicines and prevents abusive patenting of medicines
29 May 2013. Related: Treatment access.
FDA approval of generic ARVs
29 May 2013. Related: Treatment access.